National Institutes of Health, 39001-39002 [2019-16965]
Download as PDF
<![CDATA[
39001
Federal Register / Vol. 84, No. 153 / Thursday, August 8, 2019 / Notices
Dated: August 2, 2019.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–16923 Filed 8–7–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
jbell on DSK3GLQ082PROD with NOTICES
Name of Committee: National Institute on
Aging Special Emphasis Panel; T32 and T35
Review, January 2020 Council ZAG1 ZIJ–U
(J4).
Date: October 18, 2019.
Time: 8:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Anita H. Undale, MD,
Ph.D., Scientific Review Officer, Scientific
Review Branch, National Institute on Aging,
National Institutes of Health, Gateway
Building, Suite 2W200, 7201 Wisconsin
Avenue, Bethesda, MD 20892, 301–827–
7428, anita.undale@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: August 2, 2019.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–16955 Filed 8–7–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Lutetium-177
Radiotherapeutics Against
Glioblastoma Multiforme and SmallCell Lung Carcinoma
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
NIH Ref No.
Patent No. or patent
application No.
Filing date
E–150–2016–0–US–01 .............
62/333,427 ..................
May 9, 2016 ...............
E–150–2016–0–PCT–02 ...........
PCT/US2017/031696
May 9, 2017 ...............
E–150–2016–0–CN–03 .............
201780029003X .........
November 9, 2018 ......
E–150–2016–0–EP–04 ..............
17796666.0 .................
November 12, 2018 ....
E–150–2016–0–JP–05 ..............
2018–558662 ..............
November 8, 2018 ......
E–150–2016–0–US–06 .............
16/099,488 ..................
November 7, 2018 ......
E–150–2016–0–SG–07 .............
11201809982R ...........
November 9, 2018 ......
E–150–2016–1–PCT–01 ...........
PCT/US2017/054863
October 3, 2017 .........
The patent rights in these inventions
have been assigned to the Government
of the United States of America. The
prospective patent license will be
granted worldwide and in a field of use
not broader than Lutetium-177
radiotherapeutics containing RGDpeptide moieties targeting integrin
avb3-expressing glioblastoma
multiforme and small cell lung cancers.
The invention pertains to a
radiotherapeutic against cancers that
overexpress integrin avb3. RGD peptide-
VerDate Sep<11>2014
16:51 Aug 07, 2019
Jkt 247001
Frm 00075
Fmt 4703
Only written comments and/or
applications for a license which are
received by the NHLBI Office of
Technology Transfer and Development
August 23, 2019 will be considered.
DATES:
Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Michael Shmilovich, Esq.,
Senior Licensing and Patent Manager,
31 Center Drive, Room 4A29, MSC2479,
Bethesda, MD 20892–2479, phone
number 301–435–5019, or shmilovm@
mail.nih.gov.
ADDRESSES:
The
following and all continuing U.S. and
foreign patents/patent applications
thereof are the intellectual properties to
be licensed under the prospective
agreement to MTTI:
SUPPLEMENTARY INFORMATION:
Title
Chemical Conjugates of Evans Blue Derivatives and
and Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and
and Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and
and Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and
and Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and
and Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and
and Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and
and Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives And
And Imaging Agents.
targeted radionuclide therapy directed
against tumors that express integrin
avb3 has proven effective for the
treatment of advanced, low- to
intermediate-grade tumors. The subject
radiotherapeutic covered by the patent
estate includes an RGD peptide
(arginylglycylaspartic acid [Arg-GlyAsp], linear or cyclical), conjugated to
an Evans Blue (EB) analog, and further
chelated via DOTA to therapeutic
radionuclide 177Lu, a beta emitter. The
EB analog reversibly binds to circulating
PO 00000
The National Heart, Lung and
Blood Institute (NHLBI), National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to Molecular Targeting
Technologies, Inc. (MTTI); a Delaware
corporation, with its principle place of
business in West Chester, Pennsylvania,
to practice the inventions embodied in
the patent application listed in the
Supplementary Information section of
this notice.
SUMMARY:
Sfmt 4703
Their Use as Radiotherapy
Their Use as Radiotherapy
Their Use as Radiotherapy
Their Use as Radiotherapy
Their Use as Radiotherapy
Their Use as Radiotherapy
Their Use as Radiotherapy
Their Use As Radiotherapy
serum albumin and improves the
pharmacokinetics of RGD peptide
DOTA conjugated radiotherapeutics and
potentially toxicity. The EB analog
conjugated has been shown by the
inventors to provide reversible albumin
binding in vivo and extended half-life in
circulation. This notice is made in
accordance with 35 U.S.C. 209 and 37
CFR part 404. The prospective exclusive
patent license will be royalty bearing
and may be granted unless within
fifteen (15) days from the date of this
E:\FR\FM\08AUN1.SGM
08AUN1
39002
Federal Register / Vol. 84, No. 153 / Thursday, August 8, 2019 / Notices
published notice, the NHLBI receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the prospective field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive patent
license. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: August 1, 2019.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
Name of Committee: National Institute of
Allergy and Infectious Diseases, Special
Emphasis Panel; NIAID Clinical Trial
Planning Grants (R34).
Date: September 19, 2019.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Priti Mehrotra, Ph.D.,
Chief, Immunology Review Branch, Scientific
Review Program, Division of Extramural
Activities, Room #3G40, National Institutes
of Health/NIAID, 5601 Fishers Lane, MSC
9823, Bethesda, MD 20892–7616, 240–669–
5066, pmehrotra@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: August 2, 2019.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–16965 Filed 8–7–19; 8:45 am]
BILLING CODE 4140–01–P
[FR Doc. 2019–16924 Filed 8–7–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
jbell on DSK3GLQ082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases, Special
Emphasis Panel; Clinical Research Products
Management Center (CRPMC).
Date: September 3, 2019.
Time: 9:30 a.m. to 12:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Audrey O. Lau, MPH,
Ph.D., Acting Senior Scientific Review
Officer, Aids Review Branch SRP, RM 3E70,
National Institutes of Health, NIAID, 5601
Fishers Lane, MSC 9834, Rockville, MD
20852–9834, 240–669–2081, audrey.lau@
nih.gov.
VerDate Sep<11>2014
16:51 Aug 07, 2019
Jkt 247001
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; CTSA.
Date: September 11–12, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: Bethesda North Marriott Hotel &
Conference Center, Montgomery County
Conference Center Facility, 5701 Marinelli
Road, North Bethesda, MD 20852.
Contact Person: Victor Henriquez, Ph.D.,
Scientific Review Officer, Office of Scientific
Director, National Center for Advancing
Translational Sciences (NCATS), National
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
Institutes of Health, 6701 Democracy Blvd.,
Democracy 1, Room 1080, Bethesda, MD
20892–4878, 301–435–0813, henriquv@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: August 2, 2019.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–16925 Filed 8–7–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
Project: SAMHSA Application for Peer
Grant Reviewers (OMB No. 0930–
0255)—Revision
Section 501(h) of the Public Health
Service (PHS) Act (42 U.S.C. 290aa)
directs the Assistant Secretary of the
Substance Abuse and Mental Health
Services Administration (SAMHSA) to
establish such peer review groups as are
needed to carry out the requirements of
Title V of the PHS Act. SAMHSA
administers a large discretionary grants
program under authorization of Title V,
and, for many years, SAMHSA has
funded grants to provide prevention and
treatment services related to substance
abuse and mental health.
In support of its grant peer review
efforts, SAMHSA desires to continue to
expand the number and types of
reviewers it uses on these grant review
committees. To accomplish that end,
SAMHSA has determined that it is
important to proactively seek the
inclusion of new and qualified
representatives on its peer review
groups. Accordingly, SAMHSA has
developed an application form for use
by individuals who wish to apply to
serve as peer reviewers.
E:\FR\FM\08AUN1.SGM
08AUN1
]]>Agencies
[Federal Register Volume 84, Number 153 (Thursday, August 8, 2019)]
[Notices]
[Pages 39001-39002]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-16965]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Lutetium-177
Radiotherapeutics Against Glioblastoma Multiforme and Small-Cell Lung
Carcinoma
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Heart, Lung and Blood Institute (NHLBI), National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an exclusive patent license to Molecular
Targeting Technologies, Inc. (MTTI); a Delaware corporation, with its
principle place of business in West Chester, Pennsylvania, to practice
the inventions embodied in the patent application listed in the
Supplementary Information section of this notice.
DATES: Only written comments and/or applications for a license which
are received by the NHLBI Office of Technology Transfer and Development
August 23, 2019 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Michael Shmilovich, Esq., Senior Licensing and
Patent Manager, 31 Center Drive, Room 4A29, MSC2479, Bethesda, MD
20892-2479, phone number 301-435-5019, or [email protected].
SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and
foreign patents/patent applications thereof are the intellectual
properties to be licensed under the prospective agreement to MTTI:
----------------------------------------------------------------------------------------------------------------
Patent No. or patent
NIH Ref No. application No. Filing date Title
----------------------------------------------------------------------------------------------------------------
E-150-2016-0-US-01................. 62/333,427............... May 9, 2016.............. Chemical Conjugates
of Evans Blue
Derivatives and
Their Use as
Radiotherapy and
Imaging Agents.
E-150-2016-0-PCT-02................ PCT/US2017/031696........ May 9, 2017.............. Chemical Conjugates
of Evans Blue
Derivatives and
Their Use as
Radiotherapy and
Imaging Agents.
E-150-2016-0-CN-03................. 201780029003X............ November 9, 2018......... Chemical Conjugates
of Evans Blue
Derivatives and
Their Use as
Radiotherapy and
Imaging Agents.
E-150-2016-0-EP-04................. 17796666.0............... November 12, 2018........ Chemical Conjugates
of Evans Blue
Derivatives and
Their Use as
Radiotherapy and
Imaging Agents.
E-150-2016-0-JP-05................. 2018-558662.............. November 8, 2018......... Chemical Conjugates
of Evans Blue
Derivatives and
Their Use as
Radiotherapy and
Imaging Agents.
E-150-2016-0-US-06................. 16/099,488............... November 7, 2018......... Chemical Conjugates
of Evans Blue
Derivatives and
Their Use as
Radiotherapy and
Imaging Agents.
E-150-2016-0-SG-07................. 11201809982R............. November 9, 2018......... Chemical Conjugates
of Evans Blue
Derivatives and
Their Use as
Radiotherapy and
Imaging Agents.
E-150-2016-1-PCT-01................ PCT/US2017/054863........ October 3, 2017.......... Chemical Conjugates
of Evans Blue
Derivatives And
Their Use As
Radiotherapy And
Imaging Agents.
----------------------------------------------------------------------------------------------------------------
The patent rights in these inventions have been assigned to the
Government of the United States of America. The prospective patent
license will be granted worldwide and in a field of use not broader
than Lutetium-177 radiotherapeutics containing RGD-peptide moieties
targeting integrin [alpha]v[beta]3-expressing glioblastoma multiforme
and small cell lung cancers.
The invention pertains to a radiotherapeutic against cancers that
overexpress integrin [alpha]v[beta]3. RGD peptide-targeted radionuclide
therapy directed against tumors that express integrin [alpha]v[beta]3
has proven effective for the treatment of advanced, low- to
intermediate-grade tumors. The subject radiotherapeutic covered by the
patent estate includes an RGD peptide (arginylglycylaspartic acid [Arg-
Gly-Asp], linear or cyclical), conjugated to an Evans Blue (EB) analog,
and further chelated via DOTA to therapeutic radionuclide \177\Lu, a
beta emitter. The EB analog reversibly binds to circulating serum
albumin and improves the pharmacokinetics of RGD peptide DOTA
conjugated radiotherapeutics and potentially toxicity. The EB analog
conjugated has been shown by the inventors to provide reversible
albumin binding in vivo and extended half-life in circulation. This
notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive patent license will be royalty bearing and
may be granted unless within fifteen (15) days from the date of this
[[Page 39002]]
published notice, the NHLBI receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use
that are timely filed in response to this notice will be treated as
objections to the grant of the contemplated exclusive patent license.
Comments and objections submitted to this notice will not be made
available for public inspection and, to the extent permitted by law,
will not be released under the Freedom of Information Act, 5 U.S.C.
552.
Dated: August 1, 2019.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2019-16965 Filed 8-7-19; 8:45 am]
BILLING CODE 4140-01-P
